nox2: a potential immune checkpoint for inhibition in aml
Published 5 years ago • 387 plays • Length 3:21Download video MP4
Download video MP3
Similar videos
-
4:59
checkpoint inhibitors in aml
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:27
the safety and efficacy of grb2 inhibition with bp1001 in aml
-
0:52
genomic profiling at diagnosis of myeloid neoplasms
-
2:09
advances in the management of fit adults with aml
-
1:15
outcomes of non-intensive chemotherapy differ for idh1 and idh2-mutated aml
-
1:30
a phase i trial of voruciclib /- venetoclax for the treatment of nhl and aml
-
1:14
promising novel agents in aml: menin inhibitors
-
1:04
optical genome mapping to detect abnormalities in aml
-
2:43
diagnostic tools for aml
-
0:57
potential approval of quizartinib in aml & its place in the aml treatment regimen
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
6:18
biomarkers for acute myeloid leukemia (aml) – lessons from il-2 immunotherapy with hdc
-
3:10
novel aml treament approaches
-
2:51
komet-008: a phase i trial of ziftomenib combinations in kmt2a-rearranged or npm1-mutant aml
-
3:16
overcoming venetoclax resistance in aml with mcl1 inhibition
-
1:34
current research in aml
-
3:55
ziftomenib: a menin inhibitor for r/r npm1-mutated aml